Reviewing SOPHiA GENETICS (NASDAQ:SOPH) & DIAGNOS (OTCMKTS:DGNOF)

DIAGNOS (OTCMKTS:DGNOF) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

31.6% of SOPHiA GENETICS shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

DIAGNOS has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for DIAGNOS and SOPHiA GENETICS, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DIAGNOS	0	0	0	0	0.00
SOPHiA GENETICS	1	1	3	0	2.40

SOPHiA GENETICS has a consensus price target of $10.00, indicating a potential upside of 20.48%. Given SOPHiA GENETICS’s stronger consensus rating and higher probable upside, analysts plainly believe SOPHiA GENETICS is more favorable than DIAGNOS.

Valuation & Earnings

This table compares DIAGNOS and SOPHiA GENETICS”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DIAGNOS	$50,000.00	847.28	-$3.30 million	($0.04)	-8.75
SOPHiA GENETICS	$77.27 million	9.01	-$79.00 million	($1.15)	-7.22

DIAGNOS has higher earnings, but lower revenue than SOPHiA GENETICS. DIAGNOS is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DIAGNOS and SOPHiA GENETICS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DIAGNOS	-7,014.89%	N/A	-192.10%
SOPHiA GENETICS	-93.86%	-132.47%	-45.97%

Summary

SOPHiA GENETICS beats DIAGNOS on 10 of the 14 factors compared between the two stocks.

About DIAGNOS

DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.